The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
about
Interferon beta for secondary progressive multiple sclerosisOptimizing treatment success in multiple sclerosisOestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination.Clinical use of brain volumetry.Clinical relevance of brain volume measures in multiple sclerosis.Correlation between brain volume change and T2 relaxation time induced by dehydration and rehydration: implications for monitoring atrophy in clinical studies.Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.Imaging of multiple sclerosis: role in neurotherapeutics.Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review.Clinical-magnetic resonance imaging correlations in multiple sclerosis.Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis.Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.Neuroimaging in multiple sclerosis: neurotherapeutic implications.Gray matter atrophy in multiple sclerosis: a longitudinal study.Activation of endogenous neural stem cells for multiple sclerosis therapy.Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis.Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.Effect of drugs in secondary disease progression in patients with multiple sclerosis.The pathogenesis of multiple sclerosis: is it really a primary inflammatory process?Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.Interferon-beta1b for multiple sclerosis.Axon loss is an important determinant of weakness in multifocal motor neuropathy.Neutralising antibodies to IFN-beta in patients with multiple sclerosis.Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment.Brain atrophy in multiple sclerosis: what we know and would like to know.The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.Interferon-beta1b in multiple sclerosis.Interferon-beta treatment for multiple sclerosis.The relation between inflammation and neurodegeneration in multiple sclerosis brains.Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modelingGray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.An animal model of cortical and callosal pathology in multiple sclerosis.Advances in imaging to support the development of novel therapies for multiple sclerosis.Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Reliable measurements of brain atrophy in individual patients with multiple sclerosis.Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis.
P2860
Q24203879-922907C7-6357-46A8-BC28-3F267636AA94Q26771968-8656E8E7-1997-49CC-A544-AF13803DFE3DQ30479247-649344DE-9D41-469B-A808-C5470C1A46FDQ30582479-4EC04048-7A5C-46B7-A662-162A4BD1730DQ30738659-087B3DCC-D934-4A8B-B240-779352A4EB2BQ30868361-73B1A5E6-B0B0-436D-B39A-8D36E6815B62Q30885558-4E7B2C5E-3AE0-4105-87EC-DB8100D65822Q30953733-4D12E192-1A8B-411F-8730-A5C73A85F063Q30983016-D9C44BCB-92A9-4B81-806A-9E08DC9E0F5FQ30985817-B9240B6A-558A-4DB4-A2FF-97371DF8E1A6Q30989935-58717025-B7CC-4B3B-B760-675F375C7769Q31009149-A999AB7B-EA70-4BA0-A0F4-A1C25A420F0CQ31027945-D3F625FA-37DB-48C2-B762-46356D982F34Q33200189-A09582A8-8379-478A-84FA-431299A8A967Q33289264-7CDF8948-0B92-4084-A391-D8A7DD71A089Q33384098-CFAE4222-41C5-48B3-B9C3-CEBEF0BE748CQ33806032-D27741A9-18F5-401E-8ECC-3D41F1ED2ECAQ34801849-D5638D66-5B97-49B4-A100-D5C48D69F1A9Q34986269-67451125-B697-4D19-9007-8BDEFB66A04DQ35468520-644EE3BF-459D-4335-AF34-7D9B5E45A712Q35475689-0E7774CD-4E1A-4330-86DA-F262EE689026Q35818152-7E684E26-6393-4200-8E27-A413D6B10D13Q35820295-ED3A3773-10E3-4973-91C3-80E3484121ACQ35997017-F38F2C48-F422-4829-8982-8F38A9FC44E0Q36106790-FC7F0440-C319-4F2E-B2FD-617F6A5BFD9EQ36142106-9F126C98-B06E-4C0E-B467-77C1B0C12559Q36541952-4C587B42-2218-4D59-9F42-17F4700B6C1EQ36670935-7D8D3549-FE91-4468-9924-A8801CBCC715Q36722172-BC8E1FF5-CB00-4661-9252-5F625DFDC57AQ36748094-F9CA27BE-2D38-4A93-B08B-38C11648AB01Q36752915-C80E3017-7735-405C-92CF-C8B61E435F51Q36963178-A00CED05-6ECA-46F1-87BC-B631B1F065F2Q37181308-37EF1B31-542E-4F58-886C-D2478C3932D3Q37217111-EBA6F4C6-18D3-4E9E-99E2-70B74252F958Q37304222-CFD35859-01B0-41F3-A955-655558BCC149Q37584143-AAC66F97-3287-44F3-8678-1AF0713EB1CCQ37991519-9B1050B7-CF20-4F32-9657-50BD5E7718D4Q38375605-086AC344-98BE-489B-862D-1F58378767BCQ39335452-C1AC6C8B-1EE7-4079-A387-AE442C8FD052Q40997871-AA1C4A7E-FC76-4EB2-A6F0-B1A58F094CEA
P2860
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
The effect of interferon beta- ...... rogressive multiple sclerosis.
@en
The effect of interferon beta- ...... rogressive multiple sclerosis.
@nl
type
label
The effect of interferon beta- ...... rogressive multiple sclerosis.
@en
The effect of interferon beta- ...... rogressive multiple sclerosis.
@nl
prefLabel
The effect of interferon beta- ...... rogressive multiple sclerosis.
@en
The effect of interferon beta- ...... rogressive multiple sclerosis.
@nl
P2093
P2860
P356
P1433
P1476
The effect of interferon beta- ...... rogressive multiple sclerosis.
@en
P2093
A J Thompson
C Pozzilli
D H Miller
K Beckmann
P2860
P304
P356
10.1093/BRAIN/123.11.2256
P407
P478
123 ( Pt 11)
P577
2000-11-01T00:00:00Z